Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002;35(6):690-6. https://www.ncbi.nlm.nih.gov/pubmed/12203166
Baunwall SMD, Lee MM, Eriksen MK, Mullish BH, Marchesi JR, Dahlerup JF, et al. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine 2020;29-30:100642. https://www.ncbi.nlm.nih.gov/pubmed/33437951
Bishop EJ, Tiruvoipati R, Metcalfe J, Marshall C, Botha J, Kelley PG. The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study. Intern Med J 2018;48(6):651-60. https://www.ncbi.nlm.nih.gov/pubmed/29363242
Cammarota G, Masucci L, Ianiro G, Bibbo S, Dinoi G, Costamagna G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015;41(9):835-43. https://www.ncbi.nlm.nih.gov/pubmed/25728808
Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12(4):281-9. https://www.ncbi.nlm.nih.gov/pubmed/22321770
Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 2013;31(19):2493-9. https://www.ncbi.nlm.nih.gov/pubmed/23715579
Costello SP, Chung A, Andrews JM, Fraser RJ. Fecal Microbiota Transplant for Clostridium difficile Colitis-Induced Toxic Megacolon. Am J Gastroenterol 2015;110(5):775-7. https://www.ncbi.nlm.nih.gov/pubmed/25942309
Ereshefsky BJ, Alrahmany D, El Nekidy WS, Pontiggia L, Ghazi IM. Optimal vancomycin dose in the treatment of Clostridium difficile infection, antimicrobial stewardship initiative. J Chemother 2021;33(3):165-73. https://www.ncbi.nlm.nih.gov/pubmed/32715951
Eze P, Balsells E, Kyaw MH, Nair H. Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis. J Glob Health 2017;7(1):010417. https://www.ncbi.nlm.nih.gov/pubmed/28607673
Fischer M, Sipe B, Cheng YW, Phelps E, Rogers N, Sagi S, et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: A promising treatment approach. Gut Microbes 2017;8(3):289-302. https://www.ncbi.nlm.nih.gov/pubmed/28001467
Gonzales M, Pepin J, Frost EH, Carrier JC, Sirard S, Fortier LC, et al. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis 2010;10:363. https://www.ncbi.nlm.nih.gov/pubmed/21192802
Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, et al. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis 2018;18(3):296-307. https://www.ncbi.nlm.nih.gov/pubmed/29273269
Haeusler GM, Lehrnbecher T, Agyeman PKA, Loves R, Castagnola E, Groll AH, et al. Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients. Eur J Cancer 2022;171:1-9. https://www.ncbi.nlm.nih.gov/pubmed/35696884
Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021;73(5):e1029-e44. https://www.ncbi.nlm.nih.gov/pubmed/34164674
Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014;59(3):345-54. https://www.ncbi.nlm.nih.gov/pubmed/24799326
Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA 2017;318(20):1985-93. https://www.ncbi.nlm.nih.gov/pubmed/29183074
Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364(5):422-31. https://www.ncbi.nlm.nih.gov/pubmed/21288078
Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43(4):411-20. https://www.ncbi.nlm.nih.gov/pubmed/16838228
McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66(7):e1-e48. https://www.ncbi.nlm.nih.gov/pubmed/29462280
Mikamo H, Tateda K, Yanagihara K, Kusachi S, Takesue Y, Miki T, et al. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan. J Infect Chemother 2018;24(9):744-52. https://www.ncbi.nlm.nih.gov/pubmed/29934056
Miller AC, Arakkal AT, Sewell DK, Segre AM, Tholany J, Polgreen PM, et al. Comparison of Different Antibiotics and the Risk for Community-Associated Clostridioides difficile Infection: A Case-Control Study. Open Forum Infect Dis 2023;10(8):ofad413. https://www.ncbi.nlm.nih.gov/pubmed/37622034
Pai S, Aliyu SH, Enoch DA, Karas JA. Five years experience of Clostridium difficile infection in children at a UK tertiary hospital: proposed criteria for diagnosis and management. PLoS One 2012;7(12):e51728. https://www.ncbi.nlm.nih.gov/pubmed/23300561
Shetler K, Nieuwenhuis R, Wren SM, Triadafilopoulos G. Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. Surg Endosc 2001;15(7):653-9. https://www.ncbi.nlm.nih.gov/pubmed/11591962
Song YN, Yang DY, Veldhuyzen van Zanten S, Wong K, McArthur E, Song CZ, et al. Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile Infection: Systematic Review and Meta-analysis. J Can Assoc Gastroenterol 2022;5(1):e1-e11. https://www.ncbi.nlm.nih.gov/pubmed/35118227
Tixier EN, Verheyen E, Ungaro RC, Grinspan AM. Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients. Aliment Pharmacol Ther 2019;50(10):1094-9. https://www.ncbi.nlm.nih.gov/pubmed/31612528
van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021;27 Suppl 2:S1-S21. https://www.ncbi.nlm.nih.gov/pubmed/34678515
Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45(3):302-7. https://www.ncbi.nlm.nih.gov/pubmed/17599306
